The 8th International Conference On Nuclear Cardiology

29 APRIL - 2 MAY 2007

The ICNC meeting attracs a lot of attention since there is a focus on PET and CT.

Jeroen Joost Bax
Jeroen Joost Bax

During the past decade the ICNC meeting has become an important event since, in recent years, its scientific focus broadened significantly from ‘only’ nuclear cardiology to encompass Computed Tomography (CT) and Positron Emission Tomography (PET) techniques. These integrate multi-slice computed tomography and myocardial perfusion imaging into nuclear cardiology, thus allowing for combination of anatomy and function attitudes.

Co-organiser of the conference, Dr Jeroen Joost Bax MD PhD said: ‘PET and multi-slice CT have attracted a lot of attention; with PET, absolute quantification of cardiac perfusion and metabolism is possible enabling detection of coronary disease with the highest possible accuracy. Undoubtedly, the integration between multi-slice CT and PET is the area of most technical advancement used for non-invasive imaging of the coronary arteries.’ The strength of multi-slice CT is currently related to the high negative predictive value, he added. ‘This method also came a long way from originally 4-slice CT systems up to contemporary 64-slice CT systems introduced lately.’
Conference venue:

Prague, Czech Republic.
Details: www.icnc8.org/

30.08.2006

More on the subject:
Read all latest stories

Related articles

Photo

News • Noninvasive stratification

Multiplex PET helps doctors 'see' bowel cancer

Multiplex PET imaging technology could provide a ground-breaking new approach for diagnosing and treating bowel cancer patients, according to scientists in Glasgow.

Photo

Sponsored • Diagnostic imaging

Bringing mobile PET/CT to Italy

United Imaging Healthcare Europe, a leading company in advanced medical imaging and radiotherapy equipment, proudly announces the introduction of its first Mobile Digital PET/CT solution in Italy,…

Photo

News • New imaging agent

HER2-positive breast cancer: Whole-body PET/CT predicts targeted therapy response

A new imaging agent can predict early metabolic response to HER2-targeted treatment in metastatic breast cancer patients, according to new research published in the Journal of Nuclear Medicine.

Related products

Subscribe to Newsletter